Study Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous System DiseasesEnrollment118% Female48%% White61%
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMATPEP3001Data PartnerJohnson & JohnsonCondition StudiedPartial Seizure DisorderMean/Median Age (Years)1

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.